Not every diabetes visit calls for the same note. A patient coming in three months after a medication change, doing well, needs a focused note that answers one question: is the glucose controlled, and is the plan working? A patient due for their annual review needs a comprehensive note that touches every system diabetes threatens: feet, eyes, kidneys, heart, lipids, and blood pressure. Students frequently write the wrong one for the visit: a bloated comprehensive note for a quick follow-up, or a thin, focused note for a visit that was supposed to catch complications early. Choosing the right scope is the first decision a diabetes SOAP note requires, and it is the one most examples never mention.
This guide covers when a type 2 diabetes visit needs a focused SOAP note versus a comprehensive one, what each carries, and how the current 2026 ADA Standards of Care shape the assessment and plan. A worked example runs through the focused version. If you need the basic SOAP structure first, our SOAP note service and structure guide covers it. Every clinical figure here was verified against the current ADA Standards at the time of writing, because target values and drug recommendations in diabetes change year to year.
Quick Answer:
A focused type 2 diabetes SOAP note documents an interval follow-up: glucose control (A1c and self-monitoring), medication adherence and side effects, relevant symptoms, a targeted exam, and a plan to continue or adjust therapy. A comprehensive note documents the periodic full assessment: everything in the focused note plus complication screening across systems, foot exam, referral for a dilated eye exam, kidney screening (urine albumin-to-creatinine ratio and eGFR), lipids, blood pressure, immunizations, and diabetes self-management education. Use focused for interval visits, comprehensive for the annual or new-patient review. Under the 2026 ADA Standards, the A1c target is individualized (below 7 percent for most nonpregnant adults), lifestyle is first-line and metformin foundational, and cardiovascular and kidney risk reduction is now a co-primary goal: for patients with established or high cardiovascular risk, heart failure, or chronic kidney disease, a GLP-1 receptor agonist and/or an SGLT2 inhibitor is recommended irrespective of A1c.
The First Decision: Focused or Comprehensive
The scope of a diabetes note should match the purpose of the visit, and getting that match right is a clinical judgment, not a formatting choice. A focused, or problem-oriented, note is the right tool for an interval follow-up: the diagnosis is established, the question is controlled, and the note stays tight around glucose, medications, relevant symptoms, and the plan. A comprehensive note is the right tool for the periodic review, where the purpose is not just glycemic control but catching the complications diabetes causes before they progress.
Writing the wrong scope is a common and costly error. A comprehensive note for a simple interval visit buries the one relevant question, control, under systems that were not the point of the visit and may not even have been examined, which risks documenting assessments that did not happen. A focused note for an annual review misses the entire purpose of that visit, leaving complication screening undone and undocumented. The table below sets out what each note carries and when to use it, so the scope decision is deliberate rather than accidental.
Table 1: Focused vs Comprehensive Diabetes SOAP Note
Element | Focused (interval follow-up) | Comprehensive (periodic/annual review) |
|---|---|---|
Use it when | Established diagnosis; the question is glycemic control and whether the plan is working | Annual review or new patient; the purpose includes complication screening |
Subjective | Glucose self-monitoring, adherence, side effects, hypoglycemia, diet, and activity | All of the focused content, plus a full interval and complication history |
Objective | Recent A1c, BP, weight/BMI trend, targeted exam | Foot exam, dilated eye exam referral, uACR and eGFR, lipids, BP, immunization review |
Assessment | Control against the individualized A1c target, with reasoning | Glycemic control plus cardiovascular and renal risk status and complication findings |
Plan | Continue, intensify, or adjust therapy; set follow-up interval | Therapy plus complication management, referrals, self-management education, and immunizations |
What the Focused Note Carries
A focused diabetes follow-up note is disciplined about relevance. The subjective section records glucose self-monitoring results and patterns, medication adherence, and any side effects (nausea on a GLP-1 receptor agonist, genitourinary symptoms on an SGLT2 inhibitor), hypoglycemia episodes, diet and activity, and any symptoms suggesting complications. It does not re-document the entire diabetes history at every visit; that belongs to the comprehensive review.
The objective section carries the most recent A1c, relevant vitals including blood pressure, weight, or BMI trend, and a targeted exam appropriate to the visit. The assessment then states the verdict on control, whether the diabetes is at the individualized A1c target, with the reasoning that connects the A1c, the self-monitoring pattern, and the trend. Keeping the A1c number itself in the objective section and the judgment about control in the assessment is the same separation every SOAP note depends on, and it is worth being deliberate about, because the discipline of making the assessment a reasoned judgment rather than a restated diagnosis is exactly what our guide to the SOAP assessment section lays out. The plan follows from that verdict: continue, intensify, or adjust therapy, address any complication concerns, and set the interval to the next visit.
What the Comprehensive Note Adds
The comprehensive note contains everything the focused note does and then extends across every system diabetes affects. The periodic full assessment documents complication screening: a foot examination for sensation and skin integrity, a referral for or record of a dilated retinal eye examination, kidney screening with a urine albumin-to-creatinine ratio and an eGFR, a lipid panel, blood pressure with the diabetes target in mind, immunization review, and diabetes self-management education. It is the visit where the note demonstrates that the patient's whole cardiometabolic picture was reviewed, not just their glucose.
Blood pressure deserves specific attention in the comprehensive diabetes note because hypertension and diabetes travel together, and the target matters. The current guidance keeps the blood pressure target at less than 130/80 for most patients with diabetes, which aligns the diabetes note with the hypertension follow-up note, and the same control-then-adjust logic our hypertension follow-up SOAP note example walks through applies directly here. A comprehensive diabetes note that records glucose but ignores blood pressure, lipids, and kidney function has missed most of what the visit was for.
Stuck on whether your note should be focused or comprehensive? |
|---|
The scope decision is where diabetes notes most often go wrong, and it is a judgment worth a second opinion while you are learning it. Send us your case, and a nursing reviewer will tell you whether the visit calls for a focused or comprehensive note, and check that your plan reflects the current standards. Get a second read on your note, with an itemized quote back within 2 to 4 business hours, no obligation. |
The 2026 ADA Standards Behind the Plan
The plan section of any diabetes note rests on the current standards, so knowing what changed in 2026 keeps the reasoning current. The foundation is unchanged: lifestyle intervention is first-line, and metformin remains the foundational pharmacologic therapy for most patients. The A1c target stays individualized, below 7 percent for most nonpregnant adults, with less stringent targets appropriate for patients with limited life expectancy, extensive comorbidity, or a high risk of hypoglycemia.
What the 2026 Standards emphasize more strongly is that cardiovascular and kidney risk reduction is now a co-primary treatment goal, so A1c is no longer the sole measure of success. For an adult with type 2 diabetes and established or high risk of atherosclerotic cardiovascular disease, the plan should include a GLP-1 receptor agonist and/or an SGLT2 inhibitor for cardiovascular risk reduction irrespective of the A1c; for a patient with heart failure, an SGLT2 inhibitor is recommended, irrespective of A1c; and for chronic kidney disease, an SGLT2 inhibitor is central, with additional agents by criteria. The 2026 ADA Standards of Care pharmacologic section is the authoritative source for these recommendations. The practical consequence for a SOAP note is that the assessment should identify not just glycemic control but cardiovascular and renal risk, because those now drive drug selection as much as the glucose does.
A Worked Focused Diabetes SOAP Note
Consider an interval follow-up for an established patient with type 2 diabetes and known cardiovascular disease, seen three months after starting metformin, whose most recent A1c is above the individualized target. The focused note stays tight, but the assessment has to account for the cardiovascular risk, because under the current standards, that changes the plan. The worked note below shows the four sections, and its plan reflects the 2026 logic: adding an agent with cardiovascular benefit rather than simply pushing glucose-lowering alone.
Table 2: A Worked Focused Type 2 Diabetes SOAP Note
Section | What it contains for this visit |
|---|---|
Subjective | 61-year-old with type 2 diabetes and known coronary artery disease, here three months after starting metformin. Reports good adherence, no significant GI side effects, and no hypoglycemia. Home glucose readings often above target in the mornings. Diet improving; walks most days. No polyuria, blurred vision, or foot symptoms. |
Objective | A1c 8.1% (individualized target below 7%). BP 128/78. BMI stable. On metformin at an established dose, tolerating it. No acute distress; no foot lesions noted on this focused exam. |
Assessment | Type 2 diabetes, above the individualized A1c target on metformin monotherapy. Established cardiovascular disease is present, which is an independent indication for an agent with cardiovascular benefit under current standards. No evidence of acute complication today. |
Plan | Add a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit, indicated by both the above-target A1c and the established cardiovascular disease. Continue metformin and lifestyle. Reinforce home glucose monitoring. Ensure eye and kidney screening are up to date. Recheck A1c in 3 months and reassess. |
Notice that the plan adds a GLP-1 receptor agonist or SGLT2 inhibitor not only because the A1c is above target but because the patient has cardiovascular disease, which under the 2026 Standards is an indication in its own right. That is the reasoning a strong diabetes note makes visible: the drug choice is justified by both the glucose and the cardiorenal risk. The discipline of tying each plan element to an explicit indication is the same one that separates a competent note from a checklist, and it transfers to every chronic condition you document.
Common Diabetes Note Mistakes
A few errors recur in diabetes SOAP notes. The first is scope mismatch: writing a comprehensive note for an interval visit or a focused note for an annual review. The second is documenting a flat A1c target of below 7 percent as though it were universal, when the target is individualized and may be less stringent for some patients. The third is a glucose-only plan that ignores the 2026 emphasis on cardiovascular and kidney protection, missing the indication for a GLP-1 receptor agonist or SGLT2 inhibitor in a patient who qualifies, irrespective of A1c. The fourth is a comprehensive note that claims complication screening, a foot exam, or eye referral, which the documentation does not actually support.
The fix for all of these is to let the visit's purpose set the scope, and the current standards set the plan. Decide focused or comprehensive deliberately, individualize the A1c target, and build the plan around both glycemic control and cardiorenal risk. A diabetes note written this way is appropriately sized, clinically current, and defensible, and it reflects the shift the 2026 Standards make explicit: diabetes care is cardiometabolic care, not glucose management alone.
Frequently Asked Questions
When should a diabetes SOAP note be focused versus comprehensive?
Use a focused note for interval follow-up visits, where the diagnosis is established and the question is glycemic control and whether the plan is working. Use a comprehensive note for the periodic full assessment, typically annual or for a new patient, where the purpose includes complication screening across systems: feet, eyes, kidneys, lipids, and blood pressure. Matching the scope to the visit's purpose is the first decision the note requires, and writing the wrong scope is a common error.
What is the A1c target in the 2026 ADA Standards?
The A1c target is individualized. For most nonpregnant adults, it is below 7 percent, but a less stringent target may be appropriate for patients with limited life expectancy, extensive comorbidity, or a high risk of hypoglycemia. In a SOAP note, state the target as individualized to the patient rather than applying a flat universal number, and judge control against that individualized target in the assessment.
How do the 2026 Standards change diabetes drug choice?
The 2026 ADA Standards keep lifestyle as first-line and metformin as foundational, but they elevate cardiovascular and kidney risk reduction to a co-primary goal, so A1c is no longer the only measure of success. For patients with established or high atherosclerotic cardiovascular disease risk, a GLP-1 receptor agonist and/or an SGLT2 inhibitor is recommended for cardiovascular risk reduction, irrespective of A1c; for heart failure, an SGLT2 inhibitor is recommended, irrespective of A1c; and for chronic kidney disease, an SGLT2 inhibitor is central. The plan should reflect these indications, not glucose alone.
What goes in the objective section of a diabetes note?
The objective section carries the most recent A1c, relevant vitals including blood pressure, weight, or BMI trend, and the exam findings appropriate to the visit, plus, in a comprehensive note, the complication screening performed (foot exam, kidney labs, and so on). Keep the A1c value and exam findings in the objective section and reserve judgment about whether the diabetes is controlled for the assessment, maintaining the separation between measured data and clinical conclusion.
Do I document blood pressure in a diabetes SOAP note?
Yes, particularly in a comprehensive note. Hypertension and diabetes commonly coexist, and the blood pressure target for most patients with diabetes is less than 130/80. Recording and addressing blood pressure is part of the cardiometabolic review that a diabetes visit is meant to perform, and it aligns the diabetes note with the same target and control logic used in a hypertension follow-up note.
You May Also Find Useful
Match the Note to the Visit
A type 2 diabetes SOAP note starts with a decision most examples skip: focused or comprehensive. Match the scope to the visit's purpose, keep a focused note tight around control, and a comprehensive note broad across complications, individualize the A1c target, and build the plan on the current 2026 Standards, where cardiovascular and kidney protection now sit alongside glucose as a co-primary goal. Verify the targets and drug recommendations against the current Standards rather than writing from memory, because diabetes guidance updates every year. A note built this way is the right size for the visit, current with the guideline, and defensible, and it reflects what diabetes care has become: management of the whole cardiometabolic picture, not the glucose alone.
If you are learning to document diabetes visits and want your notes reviewed against the current Standards, tell us what you are working on. You will receive an itemized quote within 2 to 4 business hours, with no obligation.
